In This Article:
Myriad Genetics, Inc. MYGN recently announced an agreement with Hannah Storm, a nationally renowned sports broadcaster who recently revealed her battle with breast cancer. Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program, which features the MyRisk with RiskScore Hereditary Cancer test.
The latest collaboration with Storm will bolster the company’s Hereditary Cancer testing business.
MYGN Stock’s Likely Trend Following the News
Myriad Genetic’s shares edged up 0.5% in the after-hours trading yesterday.
The company has been gaining synergies from its MyRisk Hereditary Cancer Test. In December 2024, the American Journal of Human Genetics named the MyRisk Hereditary Cancer Test with RiskScore study as one of the top 10 significant advances in genomic medicine.
Moreover, MyRisk is expected to continue its strong growth from expanded guidelines and acceleration of EMR integrations. Accordingly, we expect the latest collaboration with Hannah Storm to boost the market sentiment toward MYGN stock.
Myriad Genetics has a market capitalization of $1.21 billion. The company's 2024 earnings are expected to increase 144.4% from the 2023 figure. MYGN delivered an average earnings surprise of 247.73% in the trailing four quarters.
More on MYGN’s Collaboration With Hannah Storm
Hannah Storm is a longtime SportsCenter and NBC sports anchor. In January 2024, she was diagnosed with stage zero ductal carcinoma in situ (DCIS). A routine mammogram detected something suspicious, prompting an ultrasound, which led to a biopsy that revealed DCIS. Since then, she has been raising awareness about the importance of knowing one’s family health history.
Under the agreement, she will promote the importance of collecting a detailed family health history for cancer and understanding the associated cancer risks on her social media platforms. She plans to share several posts about how to have conversations with your family about hereditary cancers, the importance of knowing both sides of your family health history and what questions to ask.
Per Myriad Genetics, collaborating with someone like Storm will encourage more women to engage in conversations about their family’s health history and consider preventive steps in consultation with their healthcare providers.
About MYGN’s MyRisk Hereditary Cancer Test With RiskScore
MyRisk with RiskScore evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with increased cancer risk for 11 different cancers. When combined with family history and other clinical factors such as breast density, MyRisk with RiskScore provides eligible patients with a five-year and remaining lifetime breast cancer risk assessment.